Abstract
Matrix metalloproteinases (MMPs) have been implicated in the invasion, metastasis, and angiogenesis associated with human cancer by mediating the degradation of extracellular matrix components. In this paper, we report data that show that BAY 12-9566, a novel inhibitor of MMPs, inhibits angiogenesis, tumor regrowth, and the growth of lung metastases. BAY 12-9566, at 15–100 μM, inhibited tubule formation by human endothelial cells in an in vitro model, but did not prevent the proliferation of endothelial and human breast cancer cells. In the MDA-MB-435 human mammary carcinoma xenograft model, in which the primary tumor is transplanted into the murine mammary fat pad, BAY 12-9566, administered daily at a dose of 100 mg/kg/day p.o. after resection of the primary tumor, inhibited local tumor regrowth by 58% without causing any toxic effect. In addition, BAY 12-9566 treatment inhibited the number and volume of lung metastases by 57 and 88%, respectively. These effects were highly correlated with the serum concentration of BAY 12-9566 at the end of treatment. The serum of the treated animals, harvested 24 h after the last treatment, and the tumor regrown at the site of tumor transplant in the treated animals, contained less protein with MMP-9 activity (as measured in a gelatin zymography assay) than the corresponding controls. However, no difference in the activity of MMP-2 was observed. Although all clinical trials in cancer involving BAY 12-9566 have been halted, this MMP inhibitor has never been used in clinical trials in breast cancer. These results suggest that the novel MMP inhibitor BAY 12-9566 maybe a useful and safe oral treatment for breast cancer, adjunctive to surgery.
Similar content being viewed by others
References
Liotta LA. Tumor invasion and metastasis: role of the extracellular matrix. Cancer Res 1986; 46: 1–7.
Liotta LA, Steeg PS, Stetler—Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327–36.
Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260–70.
Fidler LJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 85–8.
Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Exp Opin Invest Drugs 2000; 9: 2167–77.
Overall CM, Lopez—Otin C. Strategies for MMP inhibition in cancer: innovations for the post—trial era. Nat Rev Cancer. 2002; 2: 657–72.
Hibner B, Card A, Flynn C et al. BAY 12–9566, a novel, biphenyl matrix metalloproteinase inhibitor, demonstrates anti—invasive and anti—angiogenic properties. Proc Am Assoc Cancer Res 1998; 39: 302.
Bull C, Flynn C, Eberwein D et al. Activity of the biphenyl matrix metalloproteinase inhibitor BAY 12–9566 in murine in vivo models. Proc Am Assoc Cancer Res 1998; 39: 302.
Flynn C, Bull C, Eberwein D et al. Anti—metastatic activity of BAY 12–9566 in a human colon carcinoma HCT116 orthotopic model. Proc Am Assoc Cancer Res 1998; 39: 301.
Nehls V, Drenckhahn D. A novel, microcarrier—based in vitro assay for rapid and reliable quantification of three—dimensional cell migration and angiogenesis. Microvasc Res 1995; 50: 311–22.
Sweeney CJ, Miller KD, Sissons S et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2—methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61: 3369–72.
Sledge GW Jr, Qulali M, Goulet R et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995; 87: 1546–50.
Brown PD, Levy AT, Margulies IM et al. Independent expression and cellular processing of Mr 72 000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 1990; 50: 6184–91.
Nozaki S, Sledge GW Jr, Nakshatri H. Inhibitor—of—kB super—repressor inhibits growth and pulmonary metastasis of MDA—MB–435 breast cancer cells in nude mice. Proc Am Assoc Cancer Res 2000; 41: 382.
Grochow L, O'Reilly S, Humphrey R et al. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI), BAY 12–95 66. Proc Am Soc Clin Oncol 1998; 17: 822.
Wojtowicz—Praga S, Low J, Marshall J et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB–94) in patients with advanced cancer. Invest New Drugs 1996; 14: 193–202.
Yu AE, Hewitt RE, Connor EW et al. Matrix metalloproteinases. Novel targets for directed cancer therapy. Drug Aging 1997; 11: 229–44.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nozaki, S., Sissons, S., Chien, DS. et al. Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model. Clin Exp Metastasis 20, 407–412 (2003). https://doi.org/10.1023/A:1025473709656
Issue Date:
DOI: https://doi.org/10.1023/A:1025473709656